Evidence map›Paper›PMID 42498814›Full record

ReviewPurinergic signalling2026

The P2X7 receptor: insights from the murine monoclonal antibody clone L4.

Ronald Sluyter, Amal Elhage, Rachael Bartlett, Debbie Watson, Leanne Stokes, Kristen K Skarratt, Stephen J Fuller, Ben J Gu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ronald SluyterMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia. rsluyter@uow.edu.au.ORCID https://orcid.org/0000-0003-4909-686X
Amal ElhageMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID http://orcid.org/0000-0003-0625-3183
Rachael BartlettMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID http://orcid.org/0000-0002-9199-1326
Debbie WatsonMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID http://orcid.org/0000-0002-6242-3944
Leanne StokesSchool of Chemistry, Pharmacy & Pharmacology, University of East Anglia, Norwich, Norfolk, UK.ORCID http://orcid.org/0000-0003-4013-6781
Kristen K SkarrattSydney Medical School Nepean, Faculty of Medicine and Health, The University of Sydney, Nepean Hospital, Penrith, NSW, Australia.ORCID http://orcid.org/0000-0003-4971-2773
Stephen J FullerSydney Medical School Nepean, Faculty of Medicine and Health, The University of Sydney, Nepean Hospital, Penrith, NSW, Australia.ORCID http://orcid.org/0000-0003-4637-7391
Ben J GuQankorey Biotechnology Co. Ltd, Changsha, China.ORCID http://orcid.org/0000-0001-5500-4453

Funding

American Kennel Club Canine Health Foundation 03181-A
6 · The paper itself

Abstract

The P2X7 receptor (or P2X7) is an ATP-gated ion channel with important roles in the immune and other body systems. Much has been garnered about P2X7 using the first published anti-human P2X7 monoclonal antibody (mAb) (clone L4). This mAb can be used to impair P2X7 channel and pore activity and events downstream of P2X7 activation in vitro and in vivo. Immunolabelling with this mAb has been used in flow and mass cytometry, confocal microscopy and immunohistochemistry to help establish the presence of P2X7 on human leukocytes and other primary cell types, as well as various malignant cell lines. This mAb has been applied to immunoprecipitate P2X7 to identify co-associated molecules to help uncover novel roles of the receptor such as phagocytosis. Recently, this mAb has been shown to mediate complement-dependent cytotoxicity, offering a new avenue of limiting P2X7-mediated processes by depleting P2X7

Indexed as

Antibodies, MonoclonalReceptors, Purinergic P2X7AnimalsHumansMiceAntibodies, MonoclonalReceptors, Purinergic P2X7Bone cellCancer cellLeukocyteNeural cellP2RX7Skin cell

Identifiers

PMID42498814
PMCPMC13400550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.